IHBT: Successful Commercialization of Hematology, Hematooncology and Immunotherapy Products

Registration number: TQ11000057

Implementation period: 2024 - 2028

Provider: Technology Agency of the Czech Republic

SIGMA Programme

The aim of the project is to strengthen the facilities of the IHBT for the validation of new gene therapy drugs and diagnostic methods, thereby increasing their market value. In addition, the project aims to improve the economic performance of the IHBT in applied research and to introduce self-sustaining financing for technology transfer. Patients of the IHBT will benefit from the availability of innovative drugs and diagnostic methods in the country. Planned outputs include clinical trials of three drugs, four new diagnostic methods and six innovative services by the end of the sustainability period. The aim is also to find reimbursement mechanisms for one third of the project outputs.